Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.89 |
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15121045 | 0.94 | PDE5A (1.00) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776560 | 0.88 | PDE5A (0.70) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776681 | 0.87 | PDE5A (0.68) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL13732888 | 0.84 | PDE5A (0.72) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15633909 | 0.83 | PDE5A (0.61) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776728 | 0.83 | PDE5A (0.77) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15120873 | 0.82 | PDE5A (0.76) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14788373 | 0.82 | PDE5A (0.70) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776436 | 0.82 | GUCY1A1 (0.66) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776884 | 0.82 | PDE5A (0.75) | PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| EP-2699578-B1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| EP-2699578-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012143510-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | TPMT, GOT2, TYMP | PDE5A 1225/4885GUCY1A1 3397/4885GUCY1B1 2530/4885 |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | PON1, QDPR, FABP3 | PDE5A 304/4885GUCY1A1 2148/4885GUCY1B1 1166/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | PDE5A 1705/4885GUCY1A1 3578/4885GUCY1B1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.